Literature DB >> 2386981

Regression mechanisms of mouse fibrosarcoma cells after in vitro exposure to quercetin: diminution of tumorigenicity with a corresponding decrease in the production of prostaglandin E2.

F Okada1, M Hosokawa, J Hasegawa, M Ishikawa, I Chiba, Y Nakamura, H Kobayashi.   

Abstract

We have previously reported that both regressor (QR) and progressor (metastatic, QP) clones were obtained after the in vitro exposure of a mouse fibrosarcoma BMT-11 cl-9 to quercetin. In this study, we investigated possible mechanisms of spontaneous regression of QR clones as compared with tumorigenic QP and BMT-11 cl-9 tumor clones. We observed that BMT-11 cl-9 cells produced relatively high amounts of prostaglandin E2 (PGE2) during in vitro culture. The average production by 11 subclones of BMT-11 cl-9 cells was 9236 +/- 2829 pg/ml whereas that by 9 QR clones was 3411 +/- 2213 pg/ml (P less than 0.02). Indomethacin not only inhibited in vitro PGE2 synthesis by QP clones (high-PGE2 producers) but also the s.c. growth of QP clones in mice. Chronological changes in host immune responses to tumor-associated antigen were measured by cytotoxic T lymphocyte (CTL) activity examined after mixed lymphocyte/tumor cell culture of spleen cells obtained from tumor-bearing mice. The CTL activity disappeared abruptly in the spleen of QP-clone-bearing mice 21 days after the inoculation of tumors, whereas the spleen cells of QR-clone-inoculated mice retained their CTL activity. We determined that the mechanism responsible for the regression of these regressor clones is not due to any qualitative or quantitative increase in pre-existing membrane antigens, nor the emergence of new antigen(s) on the cell surface of the QR clones: nor was it due to enhanced susceptibility of QR clones to natural killer cells, lymphokine-activated killer cells and macrophages. These finding suggest that the regression mechanism of QR clones may be the diminished inhibition of host response to tumor-associated antigen caused by the reduced production of PGE2 by QR clones.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2386981     DOI: 10.1007/bf01741407

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  36 in total

Review 1.  Viral xenogenization of intact tumor cells.

Authors:  H Kobayashi
Journal:  Adv Cancer Res       Date:  1979       Impact factor: 6.242

Review 2.  The biological modification of tumor cells as a means of inducing their regression: an overview.

Authors:  H Kobayashi
Journal:  J Biol Response Mod       Date:  1986-02

3.  Alteration of immunogenicity of xenogenized tumor cells in syngeneic rats by the immune responses to virus-associated antigens produced on immunizing cells.

Authors:  M Hosokawa; T Okayasu; K Ikeda; H Katoh; Y Suzuki; H Kobayashi
Journal:  Cancer Res       Date:  1983-05       Impact factor: 12.701

4.  Increased prostaglandin synthesis by macrophages from tumor-bearing mice.

Authors:  L M Pelus; R S Bockman
Journal:  J Immunol       Date:  1979-11       Impact factor: 5.422

5.  Induction of highly immunogenic variants of Lewis lung carcinoma tumor by ultraviolet irradiation.

Authors:  S Peppoloni; R B Herberman; E Gorelik
Journal:  Cancer Res       Date:  1985-06       Impact factor: 12.701

6.  Enhanced expression of class I major histocompatibility complex gene (Dk) products on immunogenic variants of a spontaneous murine carcinoma.

Authors:  D A Carlow; R S Kerbel; J T Feltis; B E Elliott
Journal:  J Natl Cancer Inst       Date:  1985-08       Impact factor: 13.506

Review 7.  Chemical xenogenization of experimental tumors.

Authors:  P Puccetti; L Romani; M C Fioretti
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

8.  Changes in the tumorigenic and metastatic properties of tumor cells treated with quercetin or 5-azacytidine.

Authors:  M Ishikawa; F Okada; J Hamada; M Hosokawa; H Kobayashi
Journal:  Int J Cancer       Date:  1987-03-15       Impact factor: 7.396

9.  Inhibition of spleen cell cytotoxic capacity toward tumor by elevated prostaglandin E2 levels in mice bearing Lewis lung carcinoma.

Authors:  M R Young; C S Hoover
Journal:  J Natl Cancer Inst       Date:  1986-08       Impact factor: 13.506

10.  Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. II. T lymphocyte-mediated cytolysis.

Authors:  T Boon; J Van Snick; A Van Pel; C Uyttenhove; M Marchand
Journal:  J Exp Med       Date:  1980-11-01       Impact factor: 14.307

View more
  15 in total

1.  Activated leukocyte cell adhesion molecule (ALCAM) and annexin II are involved in the metastatic progression of tumor cells after chemotherapy with Adriamycin.

Authors:  S Choi; M Kobayashi; J Wang; H Habelhah; F Okada; J Hamada; T Moriuchi; Y Totsuka; M Hosokawa
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

2.  Thymosin-beta4 regulates motility and metastasis of malignant mouse fibrosarcoma cells.

Authors:  Tokushige Kobayashi; Futoshi Okada; Nobuyuki Fujii; Naoko Tomita; Satoru Ito; Hiroshi Tazawa; Tetsuya Aoyama; Sung Ki Choi; Toshiyuki Shibata; Hisakazu Fujita; Masuo Hosokawa
Journal:  Am J Pathol       Date:  2002-03       Impact factor: 4.307

Review 3.  Inflammation-related carcinogenesis: current findings in epidemiological trends, causes and mechanisms.

Authors:  Futoshi Okada
Journal:  Yonago Acta Med       Date:  2014-07-30       Impact factor: 1.641

4.  Nano-scaled particles of titanium dioxide convert benign mouse fibrosarcoma cells into aggressive tumor cells.

Authors:  Kunishige Onuma; Yu Sato; Satomi Ogawara; Nobuyuki Shirasawa; Masanobu Kobayashi; Jun Yoshitake; Tetsuhiko Yoshimura; Masaaki Iigo; Junichi Fujii; Futoshi Okada
Journal:  Am J Pathol       Date:  2009-10-08       Impact factor: 4.307

5.  Inflammatory cell-mediated tumour progression and minisatellite mutation correlate with the decrease of antioxidative enzymes in murine fibrosarcoma cells.

Authors:  F Okada; K Nakai; T Kobayashi; T Shibata; S Tagami; Y Kawakami; T Kitazawa; R Kominami; S Yoshimura; K Suzuki; N Taniguchi; O Inanami; M Kuwabara; H Kishida; D Nakae; Y Konishi; T Moriuchi; M Hosokawa
Journal:  Br J Cancer       Date:  1999-02       Impact factor: 7.640

6.  Malignant progression of a mouse fibrosarcoma by host cells reactive to a foreign body (gelatin sponge).

Authors:  F Okada; M Hosokawa; J I Hamada; J Hasegawa; M Kato; M Mizutani; J Ren; N Takeichi; H Kobayashi
Journal:  Br J Cancer       Date:  1992-10       Impact factor: 7.640

7.  Cancer cell progression and chemoimmunotherapy--dual effects in the induction of resistance to therapy.

Authors:  J Hamuro; T Kikuchi; F Takatsuki; M Suzuki
Journal:  Br J Cancer       Date:  1996-02       Impact factor: 7.640

8.  Enhancement of in vitro prostaglandin E2 production by mouse fibrosarcoma cells after co-culture with various anti-tumour effector cells.

Authors:  F Okada; M Hosokawa; J Hasegawa; Y Kuramitsu; K Nakai; L Yuan; H Lao; H Kobayashi; N Takeichi
Journal:  Br J Cancer       Date:  1994-08       Impact factor: 7.640

9.  Transforming growth factor beta 1 (TGF-beta 1) produced in tumour tissue after chemotherapy acts as a lymphokine-activated killer attractant.

Authors:  Y Kuramitsu; M Nishibe; M Kobayashi; Y Togashi; L Yuan; M Takizawa; F Okada; M Hosokawa
Journal:  Br J Cancer       Date:  1996-07       Impact factor: 7.640

10.  Overexpression of group II phospholipase A2 in human breast cancer tissues is closely associated with their malignant potency.

Authors:  S Yamashita; J Yamashita; M Ogawa
Journal:  Br J Cancer       Date:  1994-06       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.